Health Care • Biotechnology: Pharmaceutical Preparations
$139.37 ▼ -5.48
(-3.78%)
MKT CAP: $9.37B • VOL: 486.9K
52W L $75 52W H $161
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$117
MEDIAN
$156
MEAN
$159
HIGH
$190
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PTGX TAPE
PTGX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $168.64 | $160.28 | 2025-02-14 | $126.83 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $175.61 | $164.46 | 2025-02-06 | $131.01 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $158.88 | $153.31 | 2025-01-29 | $133.80 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $142.16 | — | 2025-01-17 | $136.58 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $122.65 | $132.40 | 2025-01-09 | $124.04 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $165.85 | $144.94 | 2024-12-18 | $121.25 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $135.19 | $140.76 | 2024-12-04 | $129.61 | -4.3% | 48% | C |